Background We quantified cardiovascular death and/or left ventricular (LV) dilatation in
patients from the SAVE trial to determine whether dilatation continued beyond 1 year …

Background. Left ventricular dilatation and dysfunction after myocardial infarction are major
predictors of death. In experimental and clinical studies, long-term therapy with the …

Abstract The Survival and Ventricular Enlargement (SAVE) Study demonstrated that long-
term administration of the angiotensin-converting enzyme inhibitor captopril to recent …

BACKGROUND Left ventricular enlargement after myocardial infarction increases the
likelihood of an adverse outcome. In an echocardiographic substudy of the Survival and …

LV enlargement is an important determinant of survival after AMI. Pathyphosiologic
mechanisms leading to LV dilatation after an AMI include early thinning and stretching of the …

BACKGROUND In the Survival and Ventricular Enlargement (SAVE) trial, recurrent
myocardial infarction (MI) was the most important predictor of a poor outcome and conferred …

Background—Angiotensin-converting enzyme (ACE) inhibitors have been shown to
attenuate left ventricular (LV) enlargement in association with reducing mortality after …

OBJECTIVES.: This study sought to assess the cost-effectiveness of captopril therapy for
survivors of myocardial infarction. BACKGROUND.: The recent randomized, controlled …

In a double-blind study, 99 patients (82 men, age range 40 to 75 years) with acute
myocardial infarction (AMI) were randomly assigned to receive captopril or placebo …

Background—The relation between left ventricular (LV) remodeling and ventricular
arrhythmias after myocardial infarction is poorly documented. We investigated the relations …